| 货号 | 3542/50 |
| 别名 | 5-Chloro-N-[(1S,2R)-2-hydroxy-3-(me |
| 供应商 | Tocris |
| 生物活性 | Selective glycogen phosphorylase inhibitor [IC50 values are 0.017 and 0.034 μM against human skeletal muscle glycogen phosphorylase a (huSMGPa) and liver glycogen phosphorylase a (huLGPa) respectively]. Antihyperglycemic agent. |
| 运输条件 | Blue Ice |
| 存放说明 | Ambient |
| 纯度 | >98 % |
| 计算分子量 | 415.87 |
| 分子式 | C21H22ClN3O4 |
| 可溶性/溶解性 | Soluble to 100 mM in DMSO and to 100 mM in ethanol |
| 参考文献 | Suhet al (2007) Astrocyte glycogen sustains neuronal activity during hypoglycemia: studies with the glycogen phosphorylase inhibitor CP-316,819 ([R-R*,S*]-5-chloro-N-[2-hydroxy-3-(methoxymethylamino)-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-carboxamide). J.Pharmacol.Exp.Ther. 321 45. PMID: 17251391. Freemanet al (2006) Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation site of the enzyme. Br.J.Pharmacol. 149 775. PMID: 17016495. Bakeret al (2005) Glycogen phosphorylase inhibition in type 2 diabetes therapy: a systematic evaluation of metabolic and functional effects in rat skeletal muscle. Diabetes 54 2453. PMID: 16046314. |